Drug details:
Molecular formula: C₁₉H₁₇N₃O₂S₂

Standard name: 1-phenyl-3-[4-(phenylsulfamoyl)phenyl]thiourea

Synonyms:

LED209 N-Phenyl-4-(3-phenylthioureido)benzenesulfonamide 1-Phenyl-3-(4-(phenylsulfamoyl)phenyl)thiourea N-Phenyl-4-(((phenylamino)thioxomethyl)amino)benzenesulfonamide N-Phenyl-4-(((phenylamino)thioxomethyl)amino)benzenesulphonamide Benzenesulfonamide, N-phenyl-4-(((phenylamino)thioxomethyl)amino)- Benzenesulphonamide, N-phenyl-4-(((phenylamino)thioxomethyl)amino)- N-PHENYL-4-[[(PHENYLAMINO)THIOXOMETHYL]AMINO]-BENZENESULFONAMIDE N-phenyl-4-[[(phenylamino)thioxomethyl]amino]benzenesulfonamide N-phenyl-4-{[(phenylamino) thioxomethyl]amino}-benzenesulfonamide

Curated SMILES: O=S(=O)(NC1=CC=CC=C1)C1=CC=C(NC(=S)NC2=CC=CC=C2)C=C1

Evidence for compound's anti-virulence activity:

Escherichia
Related VFcategory: Regulation
Target: QseC
Drug effect: Inhibits the binding of signals to QseC, preventing its autophosphorylation and consequently inhibiting QseC-mediated activation of virulence gene expression.
Max phase: Preclinical (in vivo)
Publication:
Rasko DA, et al., 2008. Targeting QseC signaling and virulence for antibiotic development. Science 321(5892):1078-80.

Salmonella
Related VF: QseBC
Target: QseC
Drug effect: Inhibits the binding of signals to QseC, preventing its autophosphorylation and consequently inhibiting QseC-mediated activation of virulence gene expression.
Max phase: Preclinical (in vivo)
Publication:
Rasko DA, et al., 2008. Targeting QseC signaling and virulence for antibiotic development. Science 321(5892):1078-80.